Literature DB >> 10196371

Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium.

A L Millar1, T Pal, L Madlensky, C Sherman, L Temple, A Mitri, H Cheng, V Marcus, S Gallinger, M Redston, B Bapat, S Narod.   

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited cancer syndrome caused by germline defects of mismatch repair (MMR) genes. Endometrial cancer is the most common extracolonic neoplasm in HNPCC and is the primary clinical manifestation of the syndrome in some families. The cumulative incidence of endometrial cancer among HNPCC mutation carriers is high, estimated to be from 22 to 43%. We hypothesized that women with double primary cancers of the colorectum and endometrium are likely to be members of HNPCC families. In order to determine how frequently HNPCC manifests in the context of double primary cancers, we examined alterations of two MMR genes, hMSH2 and hMLH1, in 40 unrelated women affected with double primary cancers. These cases were identified using hospital-based and population-based cancer registries in Ontario, Canada. MMR gene mutations were screened by single-strand conformation polymorphism analysis and confirmed by direct sequencing. Eighteen percent (seven of 40) were found to harbor mutations of one of the two MMR genes. Analysis of colorectal and/or endometrial tumors of mutation-negative probands found microsatellite instability in seven of 20 cases. Six of seven mutation-positive probands had strong family histories suggestive of HNPCC. First degree relatives of mutation-positive probands had a very high relative risk (RR) of colorectal cancer (RR = 8.1, CI 3. 5-15.9) and endometrial cancer (RR = 23.8, CI 6.4-61.0). The relative risk of mutation-negative cases was 2.8 (CI 1.7-4.5) for colorectal cancer and 5.4 (CI 2.0-11.7) for endometrial cancer. We recommend that all double primary patients with cancers at these sites should have a genetic evaluation, including molecular analysis for HNPCC where appropriate.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196371     DOI: 10.1093/hmg/8.5.823

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1.

Authors:  P Hutter; J Wijnen; C Rey-Berthod; I Thiffault; P Verkuijlen; D Farber; N Hamel; B Bapat; S N Thibodeau; J Burn; J Wu; E MacNamara; K Heinimann; G Chong; W D Foulkes
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

Review 2.  Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium?

Authors:  G S Charames; A L Millar; T Pal; S Narod; B Bapat
Journal:  Hum Genet       Date:  2000-12       Impact factor: 4.132

3.  Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome.

Authors:  Eva Wielders; Elly Delzenne-Goette; Rob Dekker; Martin van der Valk; Hein Te Riele
Journal:  Fam Cancer       Date:  2017-04       Impact factor: 2.375

Review 4.  Gynecologic Cancers in Lynch Syndrome/HNPCC.

Authors:  Karen H Lu; Russell R Broaddus
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.

Authors:  Maran J W Berends; Ying Wu; Rolf H Sijmons; Rob G J Mensink; Tineke van der Sluis; Jannet M Hordijk-Hos; Elisabeth G E de Vries; Harry Hollema; Arend Karrenbeld; Charles H C M Buys; Ate G J van der Zee; Robert M W Hofstra; Jan H Kleibeuker
Journal:  Am J Hum Genet       Date:  2002-01       Impact factor: 11.025

Review 6.  Endometrial cancer and Lynch syndrome: clinical and pathologic considerations.

Authors:  Larissa A Meyer; Russell R Broaddus; Karen H Lu
Journal:  Cancer Control       Date:  2009-01       Impact factor: 3.302

7.  Clinical and histomolecular endometrial tumor characterization of patients at-risk for Lynch syndrome in South of Brazil.

Authors:  Silvia Liliana Cossio; Patricia Koehler-Santos; Suzana Arenhart Pessini; Heleuza Mónego; Maria Isabel Edelweiss; Luise Meurer; Abdellatif Errami; Jordy Coffa; Hugo Bock; Maria Luiza Saraiva-Pereira; Patricia Ashton-Prolla; João Carlos Prolla
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 8.  Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.

Authors:  Karen H Lu
Journal:  Fam Cancer       Date:  2007-07-17       Impact factor: 2.375

9.  Lost opportunities for mismatch repair (MMR) screening among minority women with endometrial cancer.

Authors:  Marilyn Huang; Tegan Hunter; Lydia A Fein; Johnny Galli; Sophia George; Matthew Schlumbrecht; Kelly McCarter; Abdulrahman K Sinno; Luiz P Guido; Andre Pinto
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

10.  Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.

Authors:  Chris Stinton; Mary Jordan; Hannah Fraser; Peter Auguste; Rachel Court; Lena Al-Khudairy; Jason Madan; Dimitris Grammatopoulos; Sian Taylor-Phillips
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.